Gastric Bypass Clinical Trials

Clinical trials related to Gastric Bypass Procedure

Link Between the Metabolism of Cortisol and Bile Acids in Obese Patients Before and After Bariatric Surgery

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Bariatric surgery is currently the most efficient treatment for obesity. The sustained weight loss and metabolic improvement seen following Roux-en-Y gastric bypass (RYGB), is explained partly by modifications in hormones including bile acids (BA). After RYGB, an increased total BA pool and a reduction in hepatic cortisol exposure is observed. Hydroxysteroid 11-β dehydrogenase 1 (HSD11B1), steroid 5α-reductases (SRD5A), and steroid 5β-reductases, AKR1D1 (also a BA metabolizing enzyme), are three enzymes involved in the metabolism of cortisol in the liver and are known to participate in metabolic syndrome. Their activity has been shown to be decreased after RYGB. Interestingly, the mechanisms explaining the modification of hepatic cortisol exposure and the activity of theses enzymes after RYGB are unknown. In view of the few data suggesting a link between cortisol metabolism and bile acids, this work aim to study and characterize this link in a context of RYBP

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:

• Non-menopausal women

• BMI between 35 and 50 kg/m² included

• Social insured

• Ability to give consent

Locations
Other Locations
France
Hôpital Huriez - Service d'endocrinologie, diabétologie, nutrition et métabolisme
RECRUITING
Lille
Contact Information
Primary
Stéphanie ESPIARD, MD
stephanie.espiard@chru-lille.fr
0320445962
Time Frame
Start Date: 2023-03-30
Estimated Completion Date: 2026-12-30
Participants
Target number of participants: 30
Treatments
Obese/non-diabetic patients undergoing gastric bypass surgery
Sponsors
Leads: University Hospital, Lille

This content was sourced from clinicaltrials.gov